|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2008-8-21
|
|
pubmed:abstractText |
We analysed the outcomes of autologous stem cell transplantation (ASCT) following high-dose therapy with respect to remission status at the time of transplantation and induction regimen used in 56 consecutive patients with mantle cell lymphoma (MCL). Twenty-one patients received induction chemotherapy with HyperCVAD with or without rituximab (+/-R) followed by ASCT in first complete or partial remission (CR1/PR1), 15 received CHOP (+/-R) followed by ASCT in CR1/PR1 and 20 received ASCT following disease progression. Estimates of overall and progression-free survival (PFS) at 3 years among patients transplanted in CR1/PR1 were 93% and 63% compared with 46% and 36% for patients transplanted with relapsed/refractory disease, respectively. The hazard of mortality among patients transplanted with relapsed/refractory disease was 6.09 times that of patients transplanted in CR1/PR1 (P = 0.006). Patients in the CHOP (+/-R) group had a higher risk of failure for PFS compared with patients in the HyperCVAD (+/-R) group, though the difference did not reach statistical significance (hazard ratio 3.67, P = 0.11). These results suggest that ASCT in CR1/PR1 leads to improved survival outcomes for patients with MCL compared to ASCT with relapsed/refractory disease, and a HyperCVAD (+/-R) induction regimen may be associated with an improved PFS among patients transplanted in CR1/PR1.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-10561309,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-10673518,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-11128815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-11870171,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-11920175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-11964278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-12152990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-12614212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-12663455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-12890145,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-14669282,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-14760123,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-15477221,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-15591112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-15625543,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-15668467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-15781489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-16104036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-16145068,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-16266909,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-16531272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-16878325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-17089127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-18452075,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-7612491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-8946940,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-9296227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-9440717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-9452276,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-9640217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18452065-9704731
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1029-2403
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1062-73
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18452065-Adult,
pubmed-meshheading:18452065-Aged,
pubmed-meshheading:18452065-Antibodies, Monoclonal,
pubmed-meshheading:18452065-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18452065-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18452065-Combined Modality Therapy,
pubmed-meshheading:18452065-Cyclophosphamide,
pubmed-meshheading:18452065-Dexamethasone,
pubmed-meshheading:18452065-Disease-Free Survival,
pubmed-meshheading:18452065-Doxorubicin,
pubmed-meshheading:18452065-Female,
pubmed-meshheading:18452065-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:18452065-Humans,
pubmed-meshheading:18452065-Lymphoma, Mantle-Cell,
pubmed-meshheading:18452065-Male,
pubmed-meshheading:18452065-Middle Aged,
pubmed-meshheading:18452065-Neoplasm Recurrence, Local,
pubmed-meshheading:18452065-Prednisone,
pubmed-meshheading:18452065-Remission Induction,
pubmed-meshheading:18452065-Survival Rate,
pubmed-meshheading:18452065-Transplantation, Autologous,
pubmed-meshheading:18452065-Vincristine
|
|
pubmed:year |
2008
|
